GlassScriptPhysician profile
Todd B Pearlstein
NPI 1821161837
$11,411.39
in general payments reported to CMS, 2019-2025
45 companies · $561 in 2025
The $561 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,853 · 2020: $1,492 · 2021: $1,948 · 2022: $1,866 · 2023: $1,844 · 2024: $1,848 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,252.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,541.88 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,364.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,088.95 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $1,070.95 | 2019-2025 | Repatha, Evenity, Prolia |
| Janssen Pharmaceuticals, INC | $805.02 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $588.72 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $524.23 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Astellas Pharma US INC | $468.64 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $466.51 | 2019-2024 | |
| Glaxosmithkline, LLC. | $453.53 | 2019-2025 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $292.69 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $290.84 | 2019-2025 | Eliquis, Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $278.47 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $269.10 | 2020-2024 | Xifaxan, Trulance |
| Abbvie INC. | $227.99 | 2021-2025 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $212.77 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $176.66 | 2019-2022 | |
| Abbott Laboratories | $167.33 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amarin Pharma, INC. | $147.95 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $137.88 | 2019-2021 | |
| Corium, LLC | $111.13 | 2022-2024 | Azstarys |
| Exact Sciences Corporation | $75.19 | 2023-2024 | Cologuard Collection Kit |
| Dexcom, INC. | $64.09 | 2021-2024 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $56.76 | 2023 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $54.77 | 2021 | |
| Sanofi Pasteur INC. | $51.95 | 2019-2024 | |
| Shire North American Group INC | $47.32 | 2019 | |
| Depuy Synthes Sales INC. | $44.40 | 2020-2022 | |
| Eisai INC. | $42.29 | 2020-2021 | |
| Medtronic, INC. | $34.37 | 2021-2022 | |
| Allergan, INC. | $32.40 | 2019-2020 | |
| Genentech USA, INC. | $23.45 | 2019-2021 | |
| Tandem Diabetes Care, INC. | $21.09 | 2022 | |
| Hologic Sales and Service, LLC | $18.44 | 2022 | |
| Supernus Pharmaceuticals, INC. | $17.73 | 2024 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $16.75 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $16.00 | 2024 | Livalo |
| Adlon Therapeutics L.P. | $15.13 | 2020 | |
| Irhythm Technologies, INC. | $14.18 | 2023 | Zio Xt Patch |
| Averitas Pharma INC. | $14.17 | 2023 | Qutenza |
| Seqirus USA INC | $14.16 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Esperion Therapeutics, INC. | $13.14 | 2021 | |
| Bioventus LLC | $12.84 | 2022 | |
| Horizon Therapeutics Plc | $12.61 | 2019 | |
| Medtronic Minimed, INC. | $12.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Pearlstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.